
Launch of the 2021 WELBIO Investigator Programme call!
The FRFS-WELBIO announces its 2021 call for "WELBIO Investigator programmes" for basic research in the fields of life sciences that can lead to applications in all fields of (bio)technology.
The FRFS-WELBIO announces its 2021 call for "WELBIO Investigator programmes" for basic research in the fields of life sciences that can lead to applications in all fields of (bio)technology.
Le Prix Joseph Maisin en Sciences biomédicales fondamentales 2020 a été attribué à Jean-François Collet lors d’une cérémonie en présence de Sa Majesté le Roi.
Abel Garcia-Pino and his team shed light on the role played by alarmone for induction of the synthetic activity of E. coli RelA by starved ribosomes.
Abel Garcia-Pino and his team uncovered the mechanism of toxicity used by the toxin-antitoxin systems (toxSAS) in bacteria.
2020 marks the 10th anniversary of our first call for projects! Learn about our researchers, their scientific advances and how some of their discoveries have been translated into applications for human health.
François Fuks and his team demonstrated the role of the regulation of RNA epigenetics by the FTO enzyme in the development of cancer metastasis.
From disruptive research of scientific founder Benoit Vanhollebeke to the development of blood-brain barrier pharmaceuticals aiming at repairing neurovascular function and neurodegenerative diseases.
Patrice Cani et his team discovered the properties displayed by D. welbionis, a new bacterium present in 70% of the population, that open the doors for potential treatment for type 2 diabetes, obesity and inflammatory diseases.
Pierre Close and Francesca Rapino unfolded how the regulation of transfer RNAs and modification of their anticodon impacted the dynamics of protein synthesis and regulated protein folding and stability.
Decio Eizirik et son équipe décrivent des signatures moléculaires similaires entre différentes maladies auto-immunes, identifiant des voies clés qui pourraient être ciblées pour la thérapie.
Cédric Blanpain and his team identified the functions of FAT1, one of the most frequently mutated cancer gene drivers, uncovering that FAT1 mutations promote invasive features, metastasis and resistance to commonly used anti-cancer drugs
Cédric Blanpain is awarded the Francqui-Collen Prize for his fundamental research in cancer and stem cells biology.